Serum cholesterol levels modulate long-term efficacy of cholinesterase inhibitors in Alzheimer disease

Neuroscience Letters

Volumn 343, Issue 3, 2003, Pages 213-215

  Borroni, Barbara ^a   Pettenati, Carla ^b   Bordonali, Tania ^a   Akkawi, Nabil ^a   Di Luca, Monica ^c   Padovani, Alessandro ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Alzheimer Centre   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Alzheimer disease; Cholinesterase inhibitors; Serum cholesterol; Treatment efficacy

Indexed keywords

CHOLESTEROL; CHOLINESTERASE INHIBITOR; DONEPEZIL; RIVASTIGMINE; APOLIPOPROTEIN E; CARBAMIC ACID DERIVATIVE; INDAN DERIVATIVE; NOOTROPIC AGENT; PIPERIDINE DERIVATIVE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; BLOOD; CLINICAL TRIAL; DISEASE COURSE; GENETICS; GENOTYPE; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL ASPECT;

AGED; ALZHEIMER DISEASE; APOLIPOPROTEINS E; CARBAMATES; CHOLESTEROL; CHOLINESTERASE INHIBITORS; DISEASE PROGRESSION; FEMALE; GENOTYPE; HUMANS; INDANS; MALE; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; PHENYLCARBAMATES; PIPERIDINES;

EID: 0038209646     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(03)00336-7     Document Type: Article

References (9)

1. Borroni B., Colciaghi F., Lenzi G.L., Caimi L., Di Luca M., Padovani A. High cholesterol affects platelet APP processing in controls and in AD patients. Neurobiol. Aging. 2003;. in press.
2. Fassbender K., Simons M., Bergmann C., Stroick M., Lutjohann D., Keller P., Runz H., Kuhl S., Bertsch T., von Bergmann K., Hennerici M., Beyreuther K., Hartmann T. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. USA. 98:2001;5856-5861.
3. Fassbender K., Stroick M., Bertsch T., Ragoschke A., Kuehl S., Walter S., Walter J., Brechtel K., Muehlhauser F., Von Bergmann K., Lutjohann D. Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology. 59:2002;1257-1258.
4. Jick H., Zornberg G.L., Jick S.S., Seshadri S., Drachman D.A. Statins and the risk of dementia. Lancet. 356:2000;1627-1631.
5. Kivipelto M., Helkala E.L., Laakso M.P., Hanninen T., Hallikainen M., Alhainen K., Iivonen S., Mannermaa A., Tuomilehto J., Nissinen A., Soininen H. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann. Intern. Med. 137:2002;149-155.
6. Marx J. Alzheimer's disease. Bad for heart, bad for the mind? Science. 294:2001;508-509.
7. "312" Study Group, Mohs R.C., Doody R.S., Morris J.C., Ieni J.R., Rogers S.L., Perdomo C.A., Pratt R.D. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 57:2001;481-488.
8. Qizilbash N., Whitehead A., Higgins J., Wilcock G., Schneider L., Farlow M. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration. J. Am. Med. Assoc. 280:1998;1777-1782.
9. Refolo L.M., Pappolla M.A., LaFrancois J., Malester B., Schmidt S.D., Thomas-Bryant T., Tint G.S., Wang R., Mercken M., Petanceska S.S., Duff K.E. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 8:2001;890-899.